The targeting of vascular endothelial growth factor A (VEGFA), a crucial regulator of both
normal and pathological angiogenesis, has revealed innovative therapeutic approaches in …

Age-related macular degeneration (AMD) is still referred to as the leading cause of severe
and irreversible visual loss world-wide. The disease has a profound effect on quality of life of …

Purpose To test the hypothesis that tolerating some subretinal fluid (SRF) in patients with
neovascular age-related macular degeneration (nAMD) treated with ranibizumab using a …

Neovascular age-related macular degeneration (AMD) has undergone substantial break-
throughs in diagnostic as well as therapeutic respect, with optical coherence tomography …

Clinical trials identified intravitreal vascular endothelial growth factor inhibitors (anti-VEGF
agents) have the potential to stabilise or even improve visual acuity outcomes in …

Purpose To evaluate the efficacy and safety of ranibizumab 0.5 mg treat-and-extend (T&E)
versus monthly regimens in patients with neovascular age-related macular degeneration …

Purpose To assess prospectively a treat-and-extend (TREX) management strategy
compared with monthly dosing of intravitreal ranibizumab in treatment-naïve neovascular …

Purpose: A review of treat-and-extend regimens (TERs) with intravitreal anti–vascular
endothelial growth factor agents in retinal diseases. Methods: There is a lack of consensus …

Purpose To analyze the long-term outcomes of eyes with neovascular age-related macular
degeneration (AMD) starting treatment with vascular endothelial growth factor (VEGF) …

Purpose: To report the efficacy and safety of intravitreal ranibizumab for neovascular age-
related macular degeneration (nAMD) in real-world practice. Methods: Metaanalysis of∼ …